CN104902916B - 衍生自TGFβ的多肽及其用途 - Google Patents

衍生自TGFβ的多肽及其用途 Download PDF

Info

Publication number
CN104902916B
CN104902916B CN201380058181.7A CN201380058181A CN104902916B CN 104902916 B CN104902916 B CN 104902916B CN 201380058181 A CN201380058181 A CN 201380058181A CN 104902916 B CN104902916 B CN 104902916B
Authority
CN
China
Prior art keywords
tgf
tgfβ
polypeptide
beta
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201380058181.7A
Other languages
English (en)
Chinese (zh)
Other versions
CN104902916A (zh
Inventor
A·D·J·科里亚奥索里奥
K·里昂蒙松
T·卡尔梅纳特波蒂利亚
A·普波梅里诺
S·佩雷斯罗德里格斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centro de Immunologia Molecular
Original Assignee
Centro de Immunologia Molecular
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49765213&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN104902916(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Centro de Immunologia Molecular filed Critical Centro de Immunologia Molecular
Publication of CN104902916A publication Critical patent/CN104902916A/zh
Application granted granted Critical
Publication of CN104902916B publication Critical patent/CN104902916B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/495—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1841—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN201380058181.7A 2012-11-09 2013-10-30 衍生自TGFβ的多肽及其用途 Expired - Fee Related CN104902916B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CU20120158A CU24181B1 (es) 2012-11-09 2012-11-09 POLIPÉPTIDOS DERIVADOS DEL TGFß
CUCU/P/2012/0158 2012-11-09
PCT/CU2013/000007 WO2014071894A1 (es) 2012-11-09 2013-10-30 POLIPÉPTIDOS DERIVADOS DEL TGFβ Y SUS USOS

Publications (2)

Publication Number Publication Date
CN104902916A CN104902916A (zh) 2015-09-09
CN104902916B true CN104902916B (zh) 2018-04-13

Family

ID=49765213

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380058181.7A Expired - Fee Related CN104902916B (zh) 2012-11-09 2013-10-30 衍生自TGFβ的多肽及其用途

Country Status (27)

Country Link
US (1) US9701730B2 (enExample)
EP (1) EP2918284B1 (enExample)
JP (2) JP6298823B2 (enExample)
KR (1) KR102093494B1 (enExample)
CN (1) CN104902916B (enExample)
AR (1) AR093391A1 (enExample)
AU (1) AU2013344022B2 (enExample)
BR (1) BR112015010145B1 (enExample)
CA (1) CA2887455C (enExample)
CL (1) CL2015001252A1 (enExample)
CO (1) CO7400865A2 (enExample)
CU (1) CU24181B1 (enExample)
EA (1) EA031990B1 (enExample)
ES (1) ES2857176T3 (enExample)
IL (1) IL238621B (enExample)
JO (1) JO3502B1 (enExample)
MX (1) MX366060B (enExample)
MY (1) MY173078A (enExample)
NZ (1) NZ707850A (enExample)
PE (1) PE20150890A1 (enExample)
PH (1) PH12015500807A1 (enExample)
SG (1) SG11201502980VA (enExample)
TN (1) TN2015000129A1 (enExample)
TW (1) TWI615404B (enExample)
UA (1) UA115678C2 (enExample)
WO (1) WO2014071894A1 (enExample)
ZA (1) ZA201504462B (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018094173A1 (en) * 2016-11-18 2018-05-24 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Engineered tgf-beta monomers and their use for inhibiting tgf-beta signaling
PL238850B1 (pl) * 2017-10-19 2021-10-11 Calther Polska Spolka Z Ograniczona Odpowiedzialnoscia Aktywna forma transformującego czynnika wzrostu beta 1 (TGFβ1) do zastosowania w leczeniu pacjentów z glejakami wielopostaciowymi, w przypadku których to glejaków ponad 5% komórek nowotworowych jest EGFRvIII-pozytywna
CN119285746A (zh) * 2024-10-24 2025-01-10 湖南中晟全肽生物科技股份有限公司 作为TGF-β受体激动剂肽的化合物及其用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1328569A (zh) * 1998-11-24 2001-12-26 纳瓦拉公司科学与技术研究所 TGFβ1－抑制肽

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1087998A1 (en) * 1998-06-16 2001-04-04 Biogen, Inc. Variant type ii tgf-beta receptor fusion proteins and methods
AU778998B2 (en) 1998-09-22 2004-12-23 University Of Maryland At Baltimore Cystine knot growth factor mutants
US6677432B1 (en) * 1998-10-07 2004-01-13 Stryker Corporation Mutations of the C-terminal portion of TGF-β superfamily proteins
CA2575278A1 (en) * 2004-06-30 2006-01-19 Molecular Logix, Inc. Epidermal growth factor receptor antagonists and methods of use
US7795389B2 (en) * 2004-09-28 2010-09-14 The Board Of Regents Of The University Of Texas System Antagonizing TGF-beta activity with various ectodomains TGF-beta receptors used in combination or as fusion proteins
CN101365712A (zh) * 2005-01-11 2009-02-11 莫勒丘尔洛吉克斯有限公司 Pan-HER拮抗剂及其使用方法
GB0724051D0 (en) * 2007-12-08 2008-01-16 Medical Res Council Mutant proteins and methods for producing them
CA2796706A1 (en) * 2010-04-22 2011-10-27 The Medical Research, Infrastructure, And Health Services Fund Of The Te L Aviv Medical Center High affinity leptins and leptin antagonists

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1328569A (zh) * 1998-11-24 2001-12-26 纳瓦拉公司科学与技术研究所 TGFβ1－抑制肽

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Blockade of TGF-b enhances tumor vaccine efficacy mediated by CD8+ T cells;Shun Takaku等;《International Journal of Cancer》;UICC;20091014;第126卷;摘要 *
Structure of the TGF-β Receptor Complex Reveals Evolutionary Adaptations that have Led to Diversification of Function within the Superfamily;A. Hinck;《SSRL Science Highight》;20080530;图2及注解 *

Also Published As

Publication number Publication date
PE20150890A1 (es) 2015-06-10
KR102093494B1 (ko) 2020-03-26
EA201590914A1 (ru) 2015-09-30
AU2013344022B2 (en) 2016-12-15
KR20150083848A (ko) 2015-07-20
TWI615404B (zh) 2018-02-21
JP6298823B2 (ja) 2018-03-20
ZA201504462B (en) 2018-11-28
CA2887455C (en) 2022-05-17
PH12015500807A1 (en) 2015-06-08
UA115678C2 (uk) 2017-12-11
HK1213781A1 (zh) 2016-07-15
MX2015005875A (es) 2015-09-10
US9701730B2 (en) 2017-07-11
JO3502B1 (ar) 2020-07-05
NZ707850A (en) 2019-08-30
US20150284441A1 (en) 2015-10-08
AU2013344022A1 (en) 2015-05-28
ES2857176T3 (es) 2021-09-28
CL2015001252A1 (es) 2015-07-17
SG11201502980VA (en) 2015-06-29
EA031990B1 (ru) 2019-03-29
CN104902916A (zh) 2015-09-09
EP2918284A1 (en) 2015-09-16
JP2018111703A (ja) 2018-07-19
CU20120158A7 (es) 2014-06-27
TN2015000129A1 (en) 2016-10-03
TW201431875A (zh) 2014-08-16
MY173078A (en) 2019-12-25
CU24181B1 (es) 2016-04-25
JP6608473B2 (ja) 2019-11-20
JP2015535000A (ja) 2015-12-07
IL238621B (en) 2019-12-31
CO7400865A2 (es) 2015-09-30
CA2887455A1 (en) 2014-05-15
MX366060B (es) 2019-06-26
EP2918284B1 (en) 2021-02-17
WO2014071894A1 (es) 2014-05-15
AR093391A1 (es) 2015-06-03
BR112015010145A2 (enExample) 2017-08-22
IL238621A0 (en) 2015-06-30
BR112015010145B1 (pt) 2022-06-07

Similar Documents

Publication Publication Date Title
CN103201284B (zh) 用于癌症和慢性感染的治疗的具有激动剂活性的衍生自il-2的多肽
RU2517596C2 (ru) МОНОКЛОНАЛЬНЫЕ АНТИТЕЛА, КОТОРЫЕ СВЯЗЫВАЮТСЯ С hGM-CSF, И СОДЕРЖАЩИЕ ИХ КОМПОЗИЦИИ МЕДИЦИНСКОГО НАЗНАЧЕНИЯ
US7947265B2 (en) Fusion proteins and methods for modulation of immune response
CN110396133B (zh) 一种以白介素12为活性成分的融合蛋白型药物前体
TW201609807A (zh) Ｉｌ－１５異源二聚體蛋白及其用途
Kusters et al. Cytokines and immune responses in murine atherosclerosis
JP6608473B2 (ja) ＴＧＦβに由来するポリペプチド及びその使用
ZA200703528B (en) Immunotherapeutic formulations with Interleukin-2-neutralising capacity
HK1213781B (en) POLYPEPTIDES DERIVED FROM TGFβ AND USES THEREOF
JP2025538207A (ja) 操作されたインターロイキン－１５ポリペプチド、その複合体、およびその使用
CN118974093A (zh) 包含抗cd73抗体和il-2的融合蛋白及其用途
Farrokhi Fibrinogen Like Protein 2 (FGL2): A Novel Regulator of Macrophage M1 Polarization
Akporiaye Effect of Tumor-Derived TGF-3 on the Efficacy of Dendritic Cell Vaccines
HK1182403B (en) Polypeptides derived from il-2 having agonist activity, for the therapy of cancer and chronic infections

Legal Events

Date Code Title Description
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1213781

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20180413

CF01 Termination of patent right due to non-payment of annual fee